Energy Transfer and Verizon offer attractive yields and growth, while Pfizer's high debt load and looming patent cliff make it a stock to avoid for income-focused investors.
Pfizer is to be avoided due to high debt from the Seagen acquisition, dividend payouts exceeding free cash flow, and an upcoming patent cliff.
Energy Transfer is highlighted as a top high-yield stock benefiting from rising natural gas demand from AI data centers, with a 6.4% yield and low valuation.
Verizon is recommended for its 5.5% yield, strong free cash flow dividend coverage, and improving subscriber growth.
Investors seeking high-yield income should prioritize Energy Transfer and Verizon, which offer robust cash flow and growth potential. Conversely, Pfizer remains a cautionary tale due to significant debt from the Seagen acquisition and dividend payouts that currently exceed free cash flow.
Pfizer is struggling with high debt levels following the $43 billion Seagen acquisition and is currently paying out more in dividends than it generates in free cash flow.
Energy Transfer offers a 6.4% yield and benefits from long-term infrastructure projects tied to the growing energy needs of AI data centers.